The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Open accessAbstract
Trastuzumab resistance emerges to be a major issue in anti-human epidermal growth factor receptor 2 (HER2) therapy for breast cancers. Here, we demonstrated that miR-21 expression was up-regulated and its function was elevated in HER2(+) BT474, SKBR3, and MDA-MB-453 breast cancer cells that are induced to acquire trastuzumab resistance by long-term exposure to the antibody, whereas protein expression of the PTEN gene, a miR-21 target, was reduced. Blocking the action of miR-21 with antisense oligonucleotides re-sensitized the resistant cells to the therapeutic activities of trastuzumab by inducing growth arrest, proliferation inhibition, and G(1)-S cell cycle checking in the presence of the antibody. Ectopic expression of miR-21 in HER2(+) breast cancer cells confers resistance to trastuzumab. Rescuing PTEN expression with a p3XFLAG-PTEN-mut construct with deleted miR-21 targeting sequence at its 3' UTR restored the growth inhibition of trastuzumab in the resistant cells by inducing PTEN activation and AKT inhibition. In vivo, administering miR-21 antisense oligonucleotides restored trastuzumab sensitivity in the resistant breast cancer xenografts by inducing PTEN expression, whereas injection of miR-21 mimics conferred trastuzumab resistant in the sensitive breast tumors via PTEN silence. Up-regulatin of miR-21 in tumor biopsies obtained from patients receiving pre-operative trastuzumab therapy was associated with poor trastuzumab response. Therefore, miR-21 overexpression contributes to trastuzumab resistance in HER2(+) breast cancers and antagonizing miR-21 demonstrates therapeutic potential by sensitizing the malignancy to anti-HER2 treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J. M., Wang, Z., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4598 · Cited by 424
RetractedSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228
Yan, L.-X., Huang, X.-F., Shao, Q., Huang, M.-Y., Deng, L., Wu, Q.-L., Zeng, Y.-X., & Shao, J.-Y. (2008) · RNA · doi:10.1261/rna.1034808 · Cited by 1,148
MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Self-citationMeng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00479-08 · Cited by 888
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.023 · Cited by 830
hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer
Camps, C., Buffa, F. M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A. L., Gleadle, J. M., & Ragoussis, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1755 · Cited by 662
Löffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081133 · Cited by 637
TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN
Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., Gunn, A., Nakagawa, Y., Shimano, H., Todorov, I., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1897 · Cited by 573
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Jiang, J., Gusev, Y., Aderca, I., Mettler, T. A., Nagorney, D. M., Brackett, D. J., Roberts, L. R., & Schmittgen, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0523 · Cited by 511
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression
Zhang, Z., Li, Z., Gao, C., Chen, P., Chen, J., Liu, W., Xiao, S., & Lu, H. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.94 · Cited by 477
Self-citationMiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
Li, J., Huang, H., Sun, L., Yang, M., Pan, C., Chen, W., Wu, D., Lin, Z., Zeng, C., Yao, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3053 · Cited by 434
Self-citationHuse, J. T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S. H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., et al. (2009) · Genes & Development · doi:10.1101/gad.1777409 · Cited by 431
Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1448 · Cited by 416
Chun-zhi, Z., Lei, H., An-ling, Z., Yan-chao, F., Xiao, Y., Guang-xiu, W., Zhi-fan, J., Pei-yu, P., Qing-yu, Z., & Chun-sheng, K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-367 · Cited by 382
Zhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., Wang, B., Wang, G., Jia, Z., Pu, P., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.126 · Cited by 358
Bourguignon, L. Y. W., Spevak, C. C., Wong, G., Xia, W., & Gilad, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.027466 · Cited by 316
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells
Wang, P., Zou, F., Zhang, X., Li, H., Dulak, A., Tomko, R. J., Lazo, J. S., Wang, Z., Zhang, L., & Yu, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1996 · Cited by 308
Park, J.-K., Lee, E. J., Esau, C., & Schmittgen, T. D. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181ba82e1 · Cited by 287
Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., Xie, L., Zheng, Y., & Song, X. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-29 · Cited by 246
An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., Di Lauro, R., & Verde, P. (2009) · Oncogene · doi:10.1038/onc.2008.370 · Cited by 242
Trastuzumab-Induced HER Reprogramming in “Resistant” Breast Carcinoma Cells
Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., & Maihle, N. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1056 · Cited by 240
MicroRNA-21: From Cancer to Cardiovascular Disease
Jazbutyte, V., & Thum, T. (2010) · Current Drug Targets · doi:10.2174/138945010791591403 · Cited by 226
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion
Huang, T.-H., Wu, F., Loeb, G. B., Hsu, R., Heidersbach, A., Brincat, A., Horiuchi, D., Lebbink, R. J., Mo, Y.-Y., Goga, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006676 · Cited by 191
FoxM1 Mediates Resistance to Herceptin and Paclitaxel
Carr, J. R., Park, H. J., Wang, Z., Kiefer, M. M., & Raychaudhuri, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0545 · Cited by 180
Shi, G., Ye, D., Yao, X.-D., Zhang, S.-L., Dai, B., Zhang, H., Shen, Y.-J., Zhu, Y., Zhu, Y., Xiao, W.-J., et al. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.48 · Cited by 163
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network
Zhang, L., Deng, T., Li, X., Liu, H., Zhou, H., Ma, J., Wu, M., Zhou, M., Shen, S., Li, X., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp335 · Cited by 153
Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells
Mei, M., Ren, Y., Zhou, X., Yuan, X.-B., Han, L., Wang, G., Jia, Z., Pu, P., Kang, C., & Yao, Z. (2010) · Technology in Cancer Research & Treatment · doi:10.1177/153303461000900109 · Cited by 134
Connolly, E. C., Doorslaer, K. V., Rogler, L. E., & Rogler, C. E. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0465 · Cited by 134
Foxo3a Regulates Apoptosis by Negatively Targeting miR-21
Wang, K., & Li, P.-F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.093005 · Cited by 125
Liu, L., Jiang, Y., Zhang, H., Greenlee, A. R., & Han, Z. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.12.002 · Cited by 112
BMP-6 inhibits microRNA-21 expression in breast cancer through repressing δEF1 and AP-1
Du, J., Yang, S., An, D., Hu, F., Yuan, W., Zhai, C., & Zhu, T. (2009) · Cell Research · doi:10.1038/cr.2009.34 · Cited by 109
Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden Syndrome
Pezzolesi, M. G., Platzer, P., Waite, K. A., & Eng, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.04.005 · Cited by 106
Loayza‐Puch, F., Yoshida, Y., Matsuzaki, T., Takahashi, C., Kitayama, H., & Noda, M. (2010) · Oncogene · doi:10.1038/onc.2010.23 · Cited by 103
Chan, C. T., Metz, M. Z., & Kane, S. E. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7715-1 · Cited by 91
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80
Cited by
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Breast Cancer: Current Perspectives on the Disease Status
Fahad Ullah, M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 598
Emerging role of microRNA-21 in cancer
Feng, Y.-H., & Tsao, C.-J. (2016) · Biomedical Reports · doi:10.3892/br.2016.747 · Cited by 454
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Metadata
- Authors
- Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., & Song, E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 286
- Issue
- 21
- Pages
- 19127-19137
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2145848169
- Cited by
- 311
- References
- 50
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.